Please login to the form below

Not currently logged in
Email:
Password:

pegloticase

This page shows the latest pegloticase news and features for those working in and with pharma, biotech and healthcare.

Horizon swoops on Raptor to add rare disease products

Horizon swoops on Raptor to add rare disease products

In January it bought Crealta in a deal valued at $510m that brought in Krystexxa (pegloticase), an FDA-approved drug for chronic refractory gout.

Latest news

  • AZ moves a step closer to gout drug approval in US AZ moves a step closer to gout drug approval in US

    Another recent entrant into the market - Savient Pharmaceuticals - was unable to make headway with its Krystexxa (pegloticase) therapy and was forced to file for bankruptcy in 2013.

  • AZ files gout drug lesinurad in Europe AZ files gout drug lesinurad in Europe

    Another recent entrant into the gout market - Savient Pharmaceuticals - was forced to file for bankruptcy in 2013 after poor sales of its gout therapy Krystexxa (pegloticase).

  • Phase III data back AZ's gout drug Phase III data back AZ's gout drug

    On the other hand, another recent entrant into the market - Savient Pharmaceuticals - was forced to file for bankruptcy last year on lacklustre sales of its gout therapy Krystexxa (pegloticase).

  • Good news for AZ on gout candidate lesinurad Good news for AZ on gout candidate lesinurad

    Another company with high expectations - Savient Pharma - was forced to file for bankruptcy protection in October after sales of its gout treatment Krystexxa (pegloticase) remained stubbornly low despite being launched in

  • Savient faces bankruptcy after Krystexxa sales disappoint Savient faces bankruptcy after Krystexxa sales disappoint

    The Chapter 11 filing is primarily down to continued disappointing sales of Savient's lead product, gout treatment Krystexxa (pegloticase), which has failed to pick up sufficient revenues since its launch

More from news
Approximately 2 fully matching, plus 14 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

MAT offers an information exchange called Rapid Payer Response that allows healthcare stakeholders to secure immediate, global, expert insight and...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics